Assessing<scp>CYP</scp>2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition
Peng Duan(Cedars-Sinai Medical Center), Jian Wang(Foshan Hospital of TCM), Jeffrey W. Fisher(RTI International), Daniel González(University of North Carolina at Chapel Hill), Gilbert J. Burckart(Center for Drug Evaluation and Research), Lei Zhang(Institute of Hematology & Blood Diseases Hospital), Victor Crentsil(University of Pittsburgh), Fang Wu(Second Affiliated Hospital of Zhejiang University), Jason N. Moore(Center for Drug Evaluation and Research)
Cited by 15
Related Papers
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
Panax ginseng genome examination for ginsenoside biosynthesis
|GigaScience|2017|232